5

10

15

20

## WHAT IS CLAIMED IS:

- 1. A method for screening pharmaceuticals comprising detecting cross talk between intracellular signal from TGF- $\beta$  family receptor and an intranuclear receptor.
- 2. A method for screening pharmaceuticals which induce cross talk between intracellular signal from TGF-  $\beta$  family receptor and an intranuclear receptor.
- 3. A method for screening pharmaceuticals which inhibit cross talk between intracellular signal from TGF-  $\beta$  family receptor and an intranuclear receptor.
- 4. A method for screening pharmaceuticals comprising detecting interaction between an intranuclear receptor and Smad molecule.
- 5. The method for screening pharmaceuticals as claimed in Claim 4, characterized in that said interaction with said Smad molecule is detected by using the Two-Hybrid System.
- 6. The method for screening pharmaceuticals as claimed in Claim 4, characterized in that said interaction with said Smad molecule is detected by using antigenantibody reaction.
- 7. A method for screening of pharmaceuticals comprising detecting interaction between a transcription coupling factor and Smad molecule.
  - 8. The method for screening pharmaceuticals as

5

10

15

20

claimed in Claim 7, characterized in that said transcription coupling factor is CBP and/or p300.

- 9. A method for screening of pharmaceuticals comprising detecting interaction among an intranuclear receptor, Smad molecule and an transcription coupling factor.
- 10. The method for screening pharmaceuticals as described in Claim 9, characterized in that said transcription coupling factor is CBP and/or p300.
- 11. The method for screening pharmaceuticals as described in Claim 1, characterized in that said intranuclear receptor is vitamin D receptor.
- 12. The method for screening of pharmaceuticals as described in Claim 1, characterized in that said Smad molecule is Smad3.
- 13. A method for molecular design for pharmaceuticals characterized by using steric structural data of the binding site of Smad molecule with an intranuclear receptor and CPB and/or p300 as a transcription coupling factor.